-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Aurinia Pharmaceuticals Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2018 to Q3 2025.
- Aurinia Pharmaceuticals Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $411K, a 10.1% decline year-over-year.
- Aurinia Pharmaceuticals Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $1.8M, a 25.2% decline year-over-year.
- Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2024 was $1.7M, a 208% increase from 2023.
- Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2023 was $551K, a 69.9% decline from 2022.
- Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2022 was $1.83M, a 141% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)